Luis E. Raez: Three Key Genetic Fusions in Non-Small Cell Lung Cancer
Luis E. Raez, Director of Thoracic Oncology Program, Chief Scientific Officer and Medical Director, and Co-Director of MCI/FAU Florida Cancer Center of Excellence at Memorial Healthcare System, shared a post on LinkedIn:
“Dr. Luis E. Raez – Memorial Cancer Institute, Memorial Healthcare System, Miami, USA
Dr. Luis Raez reviews three key genetic fusions in non-small cell lung cancer (NSCLC): NTRK, RET, and NRG1.
He begins with NTRK fusions, rare but highly actionable mutations found across multiple tumor types, highlighting the remarkable responses seen with TRK inhibitors like larotrectinib and entrectinib.
Next, he discusses RET rearrangements, found in about 1-2% of lung adenocarcinomas, emphasizing the effectiveness of selective RET inhibitors such as selpercatinib and pralsetinib.
Finally, Dr. Raez addresses NRG1 fusions, an emerging and less understood aberration, often seen in invasive mucinous adenocarcinomas, where HER3-targeted therapies are showing early promise in clinical trials.
Dr. Raez underscores the importance of comprehensive molecular profiling to detect these fusions and offer patients personalized and effective treatment options.”
More posts featuring Luis E. Raez.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023